Concurrent Chemoradiotherapy With Weekly Low-Dose Cisplatin for Japanese Patients With Head and Neck Squamous Cell Carcinoma. (October 2021)

• Record Type: Journal Article
• Authors: Shinohara, Shogo; Takebayashi, Shinji; Hamaguchi, Kiyomi; Michida, Tetsuhiko; Tobe, Yota; Ikenaga, Tadashi; Yasumoto, Mami; Hamamoto, Ayami; Imagumbai, Toshiyuki; Mitsuyoshi, Takamasa; Ashida, Ryo; Iwai, Takahiro; Okabayashi, Shun
• Is Part Of: Clinical medicine insights. Oncology. Volume 15(2021)
• Publication Date: 2021-10
• Subjects: Head and neck cancer -- chemoradiotherapies -- concomitant -- cisplatin; Oncology -- Periodicals; 616.994005
• DOI: 10.1177/11795549211048417
• Languages: English
• ISSNs: 1179-5549

Abstract

Background: Concurrent chemoradiotherapy (CCRT) with tri-weekly high-dose cisplatin (HDC) is considered the standard regimen. However, due to significant toxicity, various weekly low-dose schedules have been increasingly used. We investigated the tolerability and survival of patients with head and neck squamous cell carcinoma (HNSCC) who underwent CCRT with low-dose weekly cisplatin (LDC) for Japanese population. Methods: A retrospective review was conducted among patients with HNSCC who were treated with CCRT/LDC in our institute. Ninety-five patients who met the criteria were enrolled in this study. We evaluated the cycle and cumulative cisplatin dose, completion rate of radiotherapy, adverse events, and survival outcome. Results: The mean cycles and cumulative cisplatin dose were 4.7 cycles and 187 mg/m 2 . All patients completed planned dose of radiation without prolonged breaks. Leucopoenia was the most frequent dose-limiting factor and 44% patients developed grade 3 or 4 toxicity. The 2-year overall survival and recurrence-free survival were 93% and 74%, respectively. The significant differences of survival outcomes between the patients with total cisplatin dose (⩾200 mg and <200 mg) or among age distribution (35-55, 56-75, and ⩾76) were not observed. Conclusions: Concurrent chemoradiotherapy/LDC can be safely administered with acceptable toxicity and survival outcome even if the patients with higher age, lower eGFR, and so on.